Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

Karim Fizazi, NamPhuong Tran, Luis Fein, +11

New England Journal of Medicine

Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)

Dana E. Rathkopf, Matthew R. Smith, Johann S. de Bono, +27

European Urology

UrologyOncologyAbiraterone AcetateMedicinePharmacotherapy +5

Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial

Kim N., Andrew Protheroe, Gaetano Facchini, +12

The Lancet Oncology

Patient-reported OutcomesUrologyGenitourinary CancerDeprivation TherapyMedicine +6

Phase II Trial of Antiepidermal Growth Factor Receptor Antibody C225 in Patients with Advanced Renal Cell Carcinoma

Robert J. Motzer, Robert J. Amato, Mary B. Todd, +8

Investigational New Drugs

UrologyPhase Ii TrialGenitourinary CancerMedicineRenal Pathology +3

Prognostic Factors for Survival in Patients with Metastatic Renal Cancer Treated with Biological Response Modifiers

Sridhar Mani, Mary B. Todd, Karol H. Katz, +1

The Journal of Urology

Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302

Johann S. de Bono, Matthew R. Smith, Fred Saad, +11

European Urology

A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer

Donald S. Kaufman, Michael A. Carducci, T. Kuzel, +6

Urologic Oncology Seminars and Original Investigations

Metastatic Urothelial CancerUrologyGenitourinary CancerMedicinePharmacology +4

Treatment evolution for metastatic castration‐resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real‐world data

Thomas W. Flaig, Ravi Potluri, Yvette Ng, +2

Cancer Medicine

Phase I Trial of Weekly Docetaxel With Concurrent Three-Dimensional Conformal Radiation Therapy in the Treatment of Unfavorable Localized Adenocarcinoma of the Prostate

Parvesh Kumar, Michael Perrotti, Robert E. Weiss, +4

Journal of Clinical Oncology

Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial

Cora N. Sternberg, Daniel Castellano, Gedske Daugaard, +17

The Lancet Oncology

UrologyAbiraterone AcetateMedicinePharmacologyClinical Trials +6